ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1784

Dual Function of Interleukin-33 in Fibroblast-Like Synoviocytes in Patients with Rheumatoid Arthritis

Min W. So1, Bon S. Koo1, You J. Kim1, You-G Kim1, Wook J. Seo2, Chang-K Lee1 and Bin Yoo1, 1Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 2Internal Medicine, Seoul Veterans Hospital, Seoul, South Korea

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: interleukins (IL) and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Cytokines, Mediators, and Gene Regulation

Session Type: Abstract Submissions (ACR)

Background/Purpose: IL-33 is a new member of the IL-1 cytokine family. Recent studies in an animal model of murine collagen-induced arthritis and human rheumatoid arthritis (RA) have suggested that IL-33 may be important as an endogenous danger signal (alarmin) in the pathogenesis of RA. IL-33 mRNA and protein expression are induced in RA fibroblast-like synoviocytes (FLS) following TNF-α/IL-1β stimulation, and IL-33 protein is mainly detected in the nucleus of these cells. The nuclear localization of IL-33 in IL-1β/TNF-α stimulated cells suggests that it may have a regulatory function inside the cell, as has been shown previously for IL-1α and IL-1F7b. The purpose of our study was to analyze the role of extracellular and intracellular IL-33 as an alarmin or regulator of nuclear transcription in RA FLS.

Methods: Synovial tissues from RA patients fulfilling the ACR criteria were obtained during open joint replacement. RA synovial samples were digested, subsequently cultured for 7 days and 3-passaged cells were used for all experiments. For analysis, quantitative RT-PCR, confocal analysis, western blot analysis, and ELISA were performed.

Results: IL-33 and ST2 (receptor of IL-33) mRNA expression increased in RA FLS stimulated with poly I:C (10 ug/ml) as a TLR3 ligand, IL-1β (10 ng/ml), and TNF-α (10 ng/ml). However, IL-33 release was not detected in the culture supernatant. Similar to previous observations, IL-33 was released from damaged FLS. After identification of the ST2 on FLS by confocal analysis, FLS was stimulated with IL-33. Exogenous IL-33 stimulation (10 – 100 ng/ml) of RA FLS increased IP-10 and RANKL mRNA expression and treatment with anti-ST2 blocked this expression. The role of intracellular IL-33 as a nuclear protein was evaluated using IL-33 siRNA. Silencing of IL-33 increased MMP-1, 3, 13, IL-6, 8, and MCP-1 mRNA expression compared to the scrambled control in RA FLS stimulated with poly I:C, IL-1β, and TNF-α. In addition, we observed that the silencing of IL-33 induced significant degradation of IκBα and increased of NF-κB activity. These findings reveal a novel role for IL-33 as a negative modulator of NF-κB activity.

Conclusion: IL-33 has dual, opposing functions. As a pro-inflammatory cytokine, IL-33 induced the expression of IP-10 and RANKL mRNA. These effects may induce bone erosion by enhancing osteoclastogenesis in RA. In contrast to extracellular IL-33, intracellular IL-33 acted as negative modulator of NF-κB activity and suppressed the expression of many pro-inflammatory cytokines and pro-destructive molecules in RA FLS.


Disclosure:

M. W. So,
None;

B. S. Koo,
None;

Y. J. Kim,
None;

Y. G. Kim,
None;

W. J. Seo,
None;

C. K. Lee,
None;

B. Yoo,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dual-function-of-interleukin-33-in-fibroblast-like-synoviocytes-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology